Cancer Treatment
Gilead Sciences and Unite for HER Launch Program to Support Metastatic Breast Cancer Patients
Gilead Sciences partners with Unite for HER to offer free integrative care to Black, Hispanic, and underserved metastatic breast cancer patients in the U.S., enhancing treatment adherence and quality of life.
Creative Biolabs' Cell Line Innovations Propel Antibody Therapy Advancements
Creative Biolabs' latest developments in cell line technology are revolutionizing antibody therapy, offering new hope for cancer treatment and biotech research.
Alfa Cytology Launches PARP Inhibitors Development Services for Advanced Cancer Treatment
Alfa Cytology has introduced comprehensive development services for PARP inhibitors, offering a promising avenue for more precise and personalized cancer treatments, particularly for cancers with genetic mutations like BRCA1 and BRCA2.
Creative Biolabs Expands CAR-T Therapy Development with Comprehensive CDMO Services
Creative Biolabs is offering end-to-end solutions for CAR-T therapy development, providing comprehensive services from plasmid design to viral vector manufacturing, potentially accelerating personalized cancer treatment research.
Creative Biolabs Showcases AI-Powered Drug Discovery and Innovative Antibody Technology at BioPharma Expo
Creative Biolabs demonstrates technological prowess through an AI-powered drug discovery platform, a global scholarship program for life science students, and a groundbreaking webinar on dual-function antibody technology that could revolutionize cancer treatment.
Second Medical Opinions Do Not Delay Critical Breast Cancer Treatment
A new study reveals that seeking a second medical opinion after a breast cancer diagnosis does not significantly postpone treatment initiation, potentially providing patients with greater confidence in their treatment strategy without compromising timely care.
GeoVax Secures New Patent for Innovative Cancer Treatment Approach
GeoVax Labs has received a Notice of Allowance for a patent describing a novel triple-combination cancer therapy strategy targeting solid tumors with potential to minimize systemic toxicity and enhance treatment effectiveness.
Creative Biolabs Advances Antibody-Drug Conjugate Technology with Innovative Engineering Techniques
Creative Biolabs has made significant breakthroughs in antibody-drug conjugate (ADC) development, demonstrating advanced glycosylation engineering and innovative approaches to targeting cancer treatments through bispecific and antibody-oligonucleotide conjugates.
Stem Cell Therapy: A Promising Frontier in Blood Cancer Treatment
Advancements in stem cell therapy offer hope for patients battling blood cancers like leukemia, myeloma, and lymphoma, with ongoing research exploring innovative treatment options.
Zelenirstat Shows Promise in Disrupting Triple-Negative Breast Cancer Cell Growth
Pacylex Pharmaceuticals' lead drug zelenirstat demonstrates potential to disrupt mitochondrial function in triple-negative breast cancer cells, potentially offering new insights into cancer treatment strategies.
Silexion Therapeutics Partners with Catalent to Advance Breakthrough KRAS Cancer Treatment
Silexion Therapeutics is collaborating with Catalent to develop SIL204, an innovative RNA interference therapy targeting multiple KRAS mutations in pancreatic cancer, with potential to transform treatment paradigms in a $470 billion precision medicine market.
Calidi Biotherapeutics to Showcase Innovative Cancer Immunotherapy Platform at Investor Webinar
Calidi Biotherapeutics will host an investor webinar highlighting its stem cell-based delivery platforms for oncolytic virus therapies, featuring updates on promising cancer treatment programs designed to enhance immune system response.
DoD Awards $876,000 Grant to Advance Lung Cancer Biomarker Research at Cedars-Sinai
The U.S. Department of Defense has provided funding to Cedars-Sinai Medical Center to support biomarker research for Kairos Pharma's experimental lung cancer treatment, focusing on identifying potential early intervention strategies for patients developing resistance to current therapies.
Indian Generic Cancer Drug Offers 98% Cost Reduction Compared to US Brand Name
A critical development in cancer treatment accessibility shows Indian-manufactured generic Ibrutinib (Ibrunat) is available for as little as $250 per month, compared to $15,000 for the US brand-name Imbruvica, while offering the same therapeutic benefits for blood cancer patients.
Pacylex Advances Cancer Treatment Innovation with NMT Inhibitor Technology
Pacylex Pharmaceuticals is advancing its novel cancer treatment technology through major industry conferences, showcasing both oral and antibody-drug conjugate applications of their N-myristoyltransferase inhibitors, marking a significant development in targeted cancer therapy.